Obesity Clinical Trial
Official title:
Lifestyle Intervention Forever: Healthy Weight for Pregnancy and Birth (Pilot Study)
Gaining too much weight in pregnancy is associated with adverse pregnancy complications and can have a long-term impact on maternal and offspring health, including increased risk for obesity and metabolic disease. Preventing excessive gestational weight gain could reduce adverse pregnancy outcomes and improve long-term health of mothers and offspring. Thirty obese (BMI ≥30) pregnant women will be recruited for this pilot study and randomly assigned to the Lifestyle Intervention ForEver (LIFE) program or routine care (RC). Participants will be enrolled before 18 weeks gestation and will be followed until 12 weeks after delivery. Women in the LIFE program will be given guidance on healthy eating and exercise at their regularly scheduled obstetric visits. To increase adherence to the program, a contingency management (CM) intervention offering incentives will be used to establish and maintain healthy nutrition and physical activity habits, working towards the goal of restricted weight gain (± 10lb) during their pregnancy. Three study testing visits will be scheduled for all participants: at study entry, 34-36 weeks gestation, and 12 weeks after delivering. Primary outcomes include adherence to the LIFE program, weight change in pregnancy and postpartum, and objective measures of maternal and offspring health.
The ultimate goal of this research is to examine the impact of a healthy lifestyle
intervention, targeting weight gain restriction during pregnancy in obese women
(BMI≥30kg/m2), on maternal and fetal outcomes.
The overarching research program has 3 main objectives:
1. To establish an effective contingency management behavioral program (LIFE), increasing
adherence to nutritional recommendations and exercise guidelines during pregnancy.
2. To examine the impact of the LIFE program on weight gain restriction during pregnancy
and postpartum weight loss in obese women in comparison to the RC group.
3. To examine the impact of the LIFE program on short- and long-term maternal and
offspring outcomes at study enrollment, 34-36 weeks gestation and 3 months postpartum
in obese women in comparison to the RC group.
- Maternal Outcomes: body composition; peak aerobic capacity; maternal
hormonal/metabolic profiles (fasted blood sample); obstetric parameters (incidence
of GDM, preeclampsia, cesarean deliveries, obstetric trauma and neonatal
complications)
- Offspring Outcomes: fetal growth pattern (fetal ultrasound); neonatal
anthropometry assessed ≤ 48 h of birth (crown-heel length, weight, head, chest and
waist circumferences, skinfold analyses); metabolic markers at birth (cord blood);
and infant anthropometry at 12 weeks of age (as above).
The experimental hypotheses to be tested are that participation in the LIFE intervention in
obese pregnant women will prevent excessive weight gain and/or achieve weight maintenance (±
10 lb) during pregnancy and will result in 7-10% weight loss at 12 weeks postpartum.
Secondly, we hypothesize that participation in the LIFE intervention in obese pregnant women
will be associated with improved aerobic capacity, reduced incidence of obstetric
complications and reduced rates of LGA as a result of beneficial alterations to metabolic
intrauterine environment for fetal growth.
With regard to this IRB application, we will be conducting a pilot and feasibility trial to
address the following specific aims:
1. To establish the feasibility of the LIFE program as a large-scale funded project,
including participant engagement in the intervention and all study visits.
2. To evaluate the feasibility of the LIFE program in achieving weight maintenance and
postpartum weight loss targets in obese pregnant women across all three obesity
classes.
3. To develop and refine the study materials for the LIFE program and assessment battery.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |